Share Price and Basic Stock Data
Last Updated: December 17, 2025, 11:33 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fabino Enterprises Ltd, operating in the pharmaceuticals sector, has shown a rather turbulent revenue trajectory over the years. The company reported sales of ₹3.36 Cr for FY 2023, which is a decline from ₹4.19 Cr in FY 2022. However, the latest quarterly results for Mar 2025 show a significant uptick, with sales rising to ₹13.78 Cr, indicating a potential recovery. This sharp increase could reflect improved demand or successful new product launches. Interestingly, the operating profit margin (OPM) has been quite unstable, fluctuating between 0.86% and 9.66% over reported periods. The current OPM of 0.94% suggests that while the company is generating revenue, its ability to convert this into profit remains limited, raising questions about operational efficiency. With expenses closely trailing revenue figures, the focus will need to shift towards enhancing operational efficiencies to sustain this growth in sales.
Profitability and Efficiency Metrics
The profitability metrics of Fabino Enterprises paint a mixed picture. The company recorded a net profit of ₹0.13 Cr for FY 2025, up from ₹0.01 Cr in FY 2023, indicating a positive trend. However, the return on equity (ROE) stands at a mere 3.08%, which is significantly below the threshold that many investors consider acceptable. This low ROE reflects the challenges the company faces in effectively utilizing shareholder equity to generate profits. Furthermore, the cash conversion cycle (CCC) of 51.93 days suggests a more manageable liquidity position compared to previous years where it spiked significantly. This improvement could indicate better inventory management or quicker receivables collection. Yet, the operating profit margin remains a concern, with figures hovering around 0.94%, suggesting that while sales may be increasing, profitability is not necessarily following suit at the same pace.
Balance Sheet Strength and Financial Ratios
Fabino’s balance sheet reveals a cautious yet evolving financial position. The company’s total assets stood at ₹13.01 Cr as of Mar 2025, with total borrowings of ₹1.64 Cr, which translates to a manageable debt-to-equity ratio of 0.42. This ratio suggests a conservative approach to leveraging, which can be a strength during economic downturns. The interest coverage ratio (ICR) is also a positive indicator, reported at 3.08x, showcasing that the company can comfortably meet its interest obligations. However, the reserves of ₹1.94 Cr versus borrowings indicate that the company has limited cushion for unforeseen expenses or investments. The price-to-book value (P/BV) ratio of 1.22x reflects a rather comfortable valuation in comparison to its book value, signaling that the market may not be overly pessimistic about the company’s prospects.
Shareholding Pattern and Investor Confidence
The shareholding structure of Fabino Enterprises is another area of interest. Promoters hold a substantial 56.82% stake, indicating a strong commitment to the company. This level of promoter holding typically instills confidence among retail investors, suggesting that the management has a vested interest in the company’s long-term success. However, the declining number of shareholders from 195 in Mar 2022 to 129 in Sep 2025 raises some eyebrows. This trend may indicate a lack of interest from retail investors or potential disenchantment with the stock’s performance. With public holdings at 43.18%, it appears that while the promoter confidence is high, broader investor enthusiasm may be waning. This dichotomy could lead to volatility in the stock price, especially if the company fails to deliver consistent results in the upcoming quarters.
Outlook, Risks, and Final Insight
Looking ahead, the outlook for Fabino Enterprises is a blend of cautious optimism and notable risks. The recent surge in sales could signal a turning point, yet the company must focus on translating this top-line growth into sustainable profitability. Risks include the persistent low operating margins and the volatility in shareholder numbers, which may reflect broader market sentiment. Additionally, external factors such as regulatory changes in the pharmaceutical sector could impact future performance. Investors should remain vigilant about these dynamics, weighing the potential for recovery against the backdrop of past performance. Overall, while there are positive indicators in terms of sales growth and balance sheet stability, the path forward requires a concerted effort to enhance profitability and restore investor confidence. Hence, a prudent approach would involve closely monitoring quarterly results and operational strategies in the coming periods.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 235/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,240 Cr. | 389 | 479/192 | 87.8 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.8 Cr. | 42.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 46.9 Cr. | 32.0 | 32.0/17.0 | 112 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,299.56 Cr | 1,144.54 | 51.49 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.38 | 2.05 | 2.15 | 1.04 | 2.32 | 0.94 | 5.14 | 4.25 | 13.78 |
| Expenses | 2.15 | 2.11 | 2.00 | 1.03 | 2.30 | 0.87 | 5.10 | 4.21 | 13.65 |
| Operating Profit | 0.23 | -0.06 | 0.15 | 0.01 | 0.02 | 0.07 | 0.04 | 0.04 | 0.13 |
| OPM % | 9.66% | -2.93% | 6.98% | 0.96% | 0.86% | 7.45% | 0.78% | 0.94% | 0.94% |
| Other Income | 0.00 | 0.01 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.11 | 0.18 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.07 |
| Depreciation | 0.02 | 0.00 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 |
| Profit before tax | 0.21 | -0.05 | 0.12 | 0.01 | 0.00 | 0.06 | 0.01 | 0.07 | 0.20 |
| Tax % | 0.00% | 0.00% | 16.67% | 0.00% | 33.33% | 0.00% | 28.57% | 55.00% | |
| Net Profit | 0.21 | -0.05 | 0.10 | 0.01 | 0.00 | 0.05 | 0.00 | 0.05 | 0.09 |
| EPS in Rs | 1.75 | -0.42 | 0.48 | 0.05 | 0.00 | 0.24 | 0.00 | 0.24 | 0.43 |
Last Updated: May 31, 2025, 6:05 am
Below is a detailed analysis of the quarterly data for Fabino Enterprises Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 13.78 Cr.. The value appears strong and on an upward trend. It has increased from 4.25 Cr. (Sep 2024) to 13.78 Cr., marking an increase of 9.53 Cr..
- For Expenses, as of Mar 2025, the value is 13.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.21 Cr. (Sep 2024) to 13.65 Cr., marking an increase of 9.44 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.13 Cr.. The value appears strong and on an upward trend. It has increased from 0.04 Cr. (Sep 2024) to 0.13 Cr., marking an increase of 0.09 Cr..
- For OPM %, as of Mar 2025, the value is 0.94%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.94%.
- For Other Income, as of Mar 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Sep 2024) to 0.18 Cr., marking an increase of 0.07 Cr..
- For Interest, as of Mar 2025, the value is 0.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.06 Cr. (Sep 2024) to 0.07 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Sep 2024) to 0.04 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.20 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Sep 2024) to 0.20 Cr., marking an increase of 0.13 Cr..
- For Tax %, as of Mar 2025, the value is 55.00%. The value appears to be increasing, which may not be favorable. It has increased from 28.57% (Sep 2024) to 55.00%, marking an increase of 26.43%.
- For Net Profit, as of Mar 2025, the value is 0.09 Cr.. The value appears strong and on an upward trend. It has increased from 0.05 Cr. (Sep 2024) to 0.09 Cr., marking an increase of 0.04 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.43. The value appears strong and on an upward trend. It has increased from 0.24 (Sep 2024) to 0.43, marking an increase of 0.19.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:45 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 6.01 | 18.00 | 14.46 |
| Expenses | 2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 5.90 | 17.83 | 14.59 |
| Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | 0.11 | 0.17 | -0.13 |
| OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | 1.83% | 0.94% | -0.90% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.29 | 0.33 |
| Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.02 | 0.13 | 0.15 |
| Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.07 | 0.09 |
| Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 | 0.26 | -0.04 |
| Tax % | 30.00% | 25.00% | 28.57% | 0.00% | 16.67% | 50.00% | ||
| Net Profit | 0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | 0.13 | -0.16 |
| EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 | 0.62 | -0.76 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -57.14% | 66.67% | -80.00% | 400.00% | 160.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 123.81% | -146.67% | 480.00% | -240.00% |
Fabino Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 63% |
| TTM: | 200% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 38% |
| TTM: | 160% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:51 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.15 | 0.15 | 1.20 | 2.10 | 2.10 | 2.10 | 2.10 | 2.10 |
| Reserves | 0.45 | 0.52 | 0.10 | 2.00 | 2.01 | 2.06 | 2.19 | 1.94 |
| Borrowings | 2.52 | 1.08 | 0.31 | 0.05 | 0.41 | 0.84 | 1.61 | 1.64 |
| Other Liabilities | 5.43 | 1.83 | 0.65 | 0.48 | 0.50 | 4.50 | 7.11 | 4.00 |
| Total Liabilities | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 | 9.68 |
| Fixed Assets | 0.10 | 0.08 | 0.16 | 0.17 | 0.15 | 0.24 | 0.46 | 0.42 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.05 |
| Other Assets | 8.45 | 3.50 | 2.10 | 4.46 | 4.87 | 9.21 | 12.50 | 9.21 |
| Total Assets | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 | 9.68 |
Below is a detailed analysis of the balance sheet data for Fabino Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 2.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.10 Cr..
- For Reserves, as of Sep 2025, the value is 1.94 Cr.. The value appears to be declining and may need further review. It has decreased from 2.19 Cr. (Mar 2025) to 1.94 Cr., marking a decrease of 0.25 Cr..
- For Borrowings, as of Sep 2025, the value is 1.64 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1.61 Cr. (Mar 2025) to 1.64 Cr., marking an increase of 0.03 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). It has decreased from 7.11 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 3.11 Cr..
- For Total Liabilities, as of Sep 2025, the value is 9.68 Cr.. The value appears to be improving (decreasing). It has decreased from 13.01 Cr. (Mar 2025) to 9.68 Cr., marking a decrease of 3.33 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.42 Cr.. The value appears to be declining and may need further review. It has decreased from 0.46 Cr. (Mar 2025) to 0.42 Cr., marking a decrease of 0.04 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.05 Cr..
- For Other Assets, as of Sep 2025, the value is 9.21 Cr.. The value appears to be declining and may need further review. It has decreased from 12.50 Cr. (Mar 2025) to 9.21 Cr., marking a decrease of 3.29 Cr..
- For Total Assets, as of Sep 2025, the value is 9.68 Cr.. The value appears to be declining and may need further review. It has decreased from 13.01 Cr. (Mar 2025) to 9.68 Cr., marking a decrease of 3.33 Cr..
Notably, the Reserves (1.94 Cr.) exceed the Borrowings (1.64 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.20 | -0.76 | -0.24 | 0.05 | -0.38 | -0.73 | -1.44 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 | 377.75 | 177.43 |
| Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 | 88.59 | 26.56 |
| Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 | 294.40 | 152.06 |
| Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 | 171.94 | 51.93 |
| Working Capital Days | 19.84 | 51.93 | 165.80 | 292.70 | 444.30 | 282.40 | 103.21 |
| ROCE % | 12.32% | 2.98% | 2.78% | 0.46% | 1.68% | 7.16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.29 | 0.17 | 0.05 |
| Diluted EPS (Rs.) | 0.29 | 0.17 | 0.05 |
| Cash EPS (Rs.) | 0.67 | 0.37 | 0.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.02 | 19.73 | 19.59 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.02 | 19.73 | 19.59 |
| Revenue From Operations / Share (Rs.) | 85.89 | 100.39 | 16.00 |
| PBDIT / Share (Rs.) | 1.90 | 0.62 | 0.22 |
| PBIT / Share (Rs.) | 1.51 | 0.41 | 0.07 |
| PBT / Share (Rs.) | 0.89 | 0.23 | 0.05 |
| Net Profit / Share (Rs.) | 0.29 | 0.17 | 0.05 |
| NP After MI And SOA / Share (Rs.) | 0.29 | 0.17 | 0.05 |
| PBDIT Margin (%) | 2.21 | 0.62 | 1.42 |
| PBIT Margin (%) | 1.76 | 0.41 | 0.47 |
| PBT Margin (%) | 1.04 | 0.23 | 0.36 |
| Net Profit Margin (%) | 0.33 | 0.16 | 0.32 |
| NP After MI And SOA Margin (%) | 0.33 | 0.16 | 0.32 |
| Return on Networth / Equity (%) | 1.45 | 0.86 | 0.26 |
| Return on Capital Employeed (%) | 5.29 | 1.59 | 0.35 |
| Return On Assets (%) | 0.34 | 0.23 | 0.21 |
| Long Term Debt / Equity (X) | 0.42 | 0.30 | 0.09 |
| Total Debt / Equity (X) | 0.42 | 0.30 | 0.09 |
| Asset Turnover Ratio (%) | 1.09 | 2.07 | 0.00 |
| Current Ratio (X) | 1.46 | 1.51 | 10.73 |
| Quick Ratio (X) | 1.36 | 1.37 | 8.07 |
| Inventory Turnover Ratio (X) | 14.21 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3.08 | 3.48 | 12.01 |
| Interest Coverage Ratio (Post Tax) (X) | 1.47 | 1.95 | 3.72 |
| Enterprise Value (Cr.) | 6.69 | 9.52 | 6.46 |
| EV / Net Operating Revenue (X) | 0.37 | 0.45 | 1.92 |
| EV / EBITDA (X) | 16.78 | 72.62 | 135.37 |
| MarketCap / Net Operating Revenue (X) | 0.28 | 0.39 | 1.87 |
| Price / BV (X) | 1.22 | 2.01 | 1.53 |
| Price / Net Operating Revenue (X) | 0.28 | 0.39 | 1.88 |
| EarningsYield | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Fabino Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 5. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 5. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 3. It has increased from 0.37 (Mar 24) to 0.67, marking an increase of 0.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.02. It has increased from 19.73 (Mar 24) to 20.02, marking an increase of 0.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.02. It has increased from 19.73 (Mar 24) to 20.02, marking an increase of 0.29.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 85.89. It has decreased from 100.39 (Mar 24) to 85.89, marking a decrease of 14.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 2. It has increased from 0.62 (Mar 24) to 1.90, marking an increase of 1.28.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 0.41 (Mar 24) to 1.51, marking an increase of 1.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.89. This value is within the healthy range. It has increased from 0.23 (Mar 24) to 0.89, marking an increase of 0.66.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For PBDIT Margin (%), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 10. It has increased from 0.62 (Mar 24) to 2.21, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 1.76. This value is below the healthy minimum of 10. It has increased from 0.41 (Mar 24) to 1.76, marking an increase of 1.35.
- For PBT Margin (%), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 10. It has increased from 0.23 (Mar 24) to 1.04, marking an increase of 0.81.
- For Net Profit Margin (%), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 5. It has increased from 0.16 (Mar 24) to 0.33, marking an increase of 0.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 8. It has increased from 0.16 (Mar 24) to 0.33, marking an increase of 0.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 15. It has increased from 0.86 (Mar 24) to 1.45, marking an increase of 0.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 5.29. This value is below the healthy minimum of 10. It has increased from 1.59 (Mar 24) to 5.29, marking an increase of 3.70.
- For Return On Assets (%), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has increased from 0.23 (Mar 24) to 0.34, marking an increase of 0.11.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 0.42, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 0.42, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.09. It has decreased from 2.07 (Mar 24) to 1.09, marking a decrease of 0.98.
- For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has decreased from 1.51 (Mar 24) to 1.46, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.36, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.21. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 14.21, marking an increase of 14.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.08. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 3.08, marking a decrease of 0.40.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 3. It has decreased from 1.95 (Mar 24) to 1.47, marking a decrease of 0.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.69. It has decreased from 9.52 (Mar 24) to 6.69, marking a decrease of 2.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.45 (Mar 24) to 0.37, marking a decrease of 0.08.
- For EV / EBITDA (X), as of Mar 25, the value is 16.78. This value exceeds the healthy maximum of 15. It has decreased from 72.62 (Mar 24) to 16.78, marking a decrease of 55.84.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.28, marking a decrease of 0.11.
- For Price / BV (X), as of Mar 25, the value is 1.22. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.22, marking a decrease of 0.79.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.28, marking a decrease of 0.11.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fabino Enterprises Ltd:
- Net Profit Margin: 0.33%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 5.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.45% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.47
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.36
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.49)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.33%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Jeevan Vihar Extension Near, Shubham Garden, Sonipat Haryana 131001 | info@fabinolife.com www.fabinolife.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Jain | Managing Director |
| Mr. Arihant Jain | Non Executive Director |
| Mr. Sumit Malik | Non Executive Director |
| Mr. Kuldeep Singh Solanki | Independent Director |
| Mrs. Tesu Alakh | Independent Director |
| Mrs. Vandana Jain | Additional Director |
FAQ
What is the intrinsic value of Fabino Enterprises Ltd?
Fabino Enterprises Ltd's intrinsic value (as of 17 December 2025) is 7.24 which is 72.05% lower the current market price of 25.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 5.45 Cr. market cap, FY2025-2026 high/low of 39.0/21.6, reserves of ₹1.94 Cr, and liabilities of 9.68 Cr.
What is the Market Cap of Fabino Enterprises Ltd?
The Market Cap of Fabino Enterprises Ltd is 5.45 Cr..
What is the current Stock Price of Fabino Enterprises Ltd as on 17 December 2025?
The current stock price of Fabino Enterprises Ltd as on 17 December 2025 is 25.9.
What is the High / Low of Fabino Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fabino Enterprises Ltd stocks is 39.0/21.6.
What is the Stock P/E of Fabino Enterprises Ltd?
The Stock P/E of Fabino Enterprises Ltd is .
What is the Book Value of Fabino Enterprises Ltd?
The Book Value of Fabino Enterprises Ltd is 19.2.
What is the Dividend Yield of Fabino Enterprises Ltd?
The Dividend Yield of Fabino Enterprises Ltd is 0.00 %.
What is the ROCE of Fabino Enterprises Ltd?
The ROCE of Fabino Enterprises Ltd is 7.16 %.
What is the ROE of Fabino Enterprises Ltd?
The ROE of Fabino Enterprises Ltd is 3.08 %.
What is the Face Value of Fabino Enterprises Ltd?
The Face Value of Fabino Enterprises Ltd is 10.0.